Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD38 as a therapeutic target.

George T Stevenson1

  • 1Tenovus Laboratory, Southampton University Hospitals, Southampton SO16 7AD, UK. gts1@soton.ac.uk

Molecular Medicine (Cambridge, Mass.)
|March 24, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Three major uncertainties in the antibody therapy of cancer.

Haematologica·2014
Same author

Follicular lymphoma and the immune system: from pathogenesis to antibody therapy.

Blood·2012
Same author

A standardized conversion of IgG antibody to bispecific form with inversely altered affinities for Fcγ-receptors II and III.

Molecular immunology·2011
Same author

Is antibody therapy of tumor compromised by infusion-related reactions? A case for inhibiting the activity of cyclooxygenase-2.

Leukemia research·2005
Same journal

Integrative statistical genetics prioritizes candidate ASCVD susceptibility genes across tissues.

Molecular medicine (Cambridge, Mass.)·2026
Same journal

Dopamine signaling reprograms macrophage FAO to alleviate acute lung injury by inhibiting NETosis via the CXCL10-CXCR3 axis.

Molecular medicine (Cambridge, Mass.)·2026
Same journal

An AI-augmented review of childhood atopic dermatitis biomarkers across genetic, immune, microbial, and metabolic domains.

Molecular medicine (Cambridge, Mass.)·2026
Same journal

PD-L1 and PD-L2 regulate in cell-autonomous and N-glycosylation-dependent manners the pro-tumorigenic characteristics and functions of human cancer-associated fibroblasts.

Molecular medicine (Cambridge, Mass.)·2026
Same journal

METTL3/YTHDC1 axis-mediated m<sup>6</sup>A modification of Foxo1 mRNA promote endothelial autophagic apoptosis in diabetic atherosclerosis.

Molecular medicine (Cambridge, Mass.)·2026
Same journal

Low-PSMA hormone-sensitive prostate cancer: a distinct clinical and molecular state.

Molecular medicine (Cambridge, Mass.)·2026
See all related articles

Improved anti-CD38 antibodies show potent anti-tumor activity in lymphoid malignancies like multiple myeloma. These therapies target the CD38 molecule, offering new hope for treating these challenging cancers.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • The CD38 molecule is prevalent on malignant cells in lymphoid tumors such as multiple myeloma and lymphomas.
  • CD38 is a promising therapeutic target for antibody-based cancer treatments.

Purpose of the Study:

  • To review advancements in anti-CD38 antibody therapies for lymphoid malignancies.
  • To highlight novel antibody constructs and their potential applications.

Main Methods:

  • Development of human IgG monoclonal anti-CD38 antibodies with potent cytotoxicities.
  • Selection of high-affinity, ADCC-active CD38-specific human antibodies using phage display.
  • Engineering of bispecific domain antibodies targeting CD38 and CD138.

Main Results:

Related Experiment Videos

  • Improved anti-CD38 antibodies demonstrate significant complement and cellular cytotoxicities against myeloma cells.
  • New antibody designs exhibit high affinity and antibody-dependent cellular cytotoxicity (ADCC).
  • Bispecific antibodies offer targeted toxin delivery to tumor cells.

Conclusions:

  • Advanced anti-CD38 antibody therapies show strong potential against multiple myeloma and other CD38-expressing cancers.
  • CD38-targeted therapies are expanding to include myeloid leukemias.
  • Further research is needed to address potential side effects like the retinoic acid syndrome.